2015 Update: Metastatic Neuroendocrine Tumors

2015 Update: Metastatic Neuroendocrine Tumors

Episodes

Specialty:

All

Year:

All

EP. 1: Pancreatic NETs Diagnosis and Treatment Challenges

October 29th 2015

EP. 2: Prognostic Indicators in Pancreatic Neuroendocrine Tumors

October 29th 2015

EP. 3: Determining Initial Treatment for Pancreatic NETs

October 29th 2015

EP. 4: Role of Somatostatin Analogs in Neuroendocrine Tumors

October 29th 2015

EP. 5: Chemotherapy for Neuroendocrine Tumors

October 29th 2015

EP. 6: Rationale for mTOR Inhibition in pNETs

October 29th 2015

EP. 7: Everolimus for pNETs and Carcinoid Tumors

October 29th 2015

EP. 8: Sunitinib for Pancreatic Neuroendocrine Tumors

October 29th 2015

EP. 9: Therapy Sequencing Considerations in Advanced pNETs

October 29th 2015

EP. 10: Using Combination Therapies in Advanced pNETs

October 29th 2015

EP. 11: Treating Metastases Associated With Neuroendocrine Tumors (NETs)

October 29th 2015

EP. 12: Emerging Therapies in Neuroendocrine Tumors (NETs)

October 29th 2015

EP. 13: Novel Neuroendocrine Tumor (NET) Therapies

October 29th 2015

Trending on OncLive

FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC

BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL

LITESPARK-012, XmAb819, and PE-PE Data Headline Key Kidney Cancer Findings From ESMO 2026